Show simple item record

EFFECT OF METFORMIN ADDED TO CHEMOTHERAPY ON THE SURVIVAL OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

Efecto de la metformina en la etapa de inducción en pacientes con Leucemia aguda linfoblástica y su impacto clínico en la supervivencia

dc.contributoren-US
dc.contributorEl número de registro dentro de la Institución es D1/15/103/03/57.es-ES
dc.creatorRamos Peñafiel, Christian; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorOlarte Carrillo, Irma; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorCeron Maldonado, Rafael; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorMiranda Peralta, Enrique; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorRozen Fuller, Etta; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorKassack Ipiña, Juan Julio; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorCruz Centeno, Federico; Instituto Nacional de Medicina Genomica
dc.creatorCollazo Jaloma, Juan; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.creatorMartínez Tovar, Adolofo; HOSPITAL GENERAL DE MEXICO DR EDUARDO LICEAGA
dc.date2018-04-19
dc.date.accessioned2019-11-11T18:26:43Z
dc.date.available2019-11-11T18:26:43Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6239
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/110783
dc.descriptionBackground: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and methods. We included 123 patients treated with metformin and without metformin. The dose used was 850mg PO at 8hrs intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p=0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.en-US
dc.descriptionBackground: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and methods. We included 123 patients treated with metformin and without metformin. The dose used was 850mg PO at 8hrs intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p=0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6239/4163
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31319
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31320
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31323
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31324
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31810
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31811
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31813
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31814
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31815
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/31816
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34320
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34321
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34322
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34323
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34324
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34325
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34326
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34410
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34618
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34619
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/34620
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/35379
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/35380
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6239/35861
dc.sourceRevista Médica de Chile; Vol. 146, núm. 7 (2018): JULIO 2018es-ES
dc.source0034-9887
dc.subjectMetformin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Therapeuticsen-US
dc.subjectMetformin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Therapeuticses-ES
dc.titleEFFECT OF METFORMIN ADDED TO CHEMOTHERAPY ON THE SURVIVAL OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIAen-US
dc.titleEfecto de la metformina en la etapa de inducción en pacientes con Leucemia aguda linfoblástica y su impacto clínico en la supervivenciaes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record